Launch of Adjutor Healthcare (NZ) Limited

Adjutor Healthcare announces launch of Adjutor Healthcare New Zealand Limited consulting and sponsorship entity for medicines and medical devices.

This is a very exciting day for me, a Kiwi living and working in Australia. Today, we officially launched our New Zealand entity Adjutor Healthcare (NZ) Limited.

The mission of Adjutor Healthcare (NZ) Limited, and parent company Adjutor Healthcare Pty Ltd is three-fold.

Firstly, we want to help bring international business to the Australia/New Zealand biotech scene and local providers. This includes contract science, contract manufacturing, clinical trials, regulatory and commercialisation.

We know that local experts are well placed to assist international clients with product development and there are many advantages that our region can provide, particularly in the clinical trial space, including: quick study start up, adherence to cGCP, IP security and reasonable cost structures.

Secondly, Adjutor aims to bring more products to Australia and New Zealand patients either through access to clinical trials or as approved products.

Thirdly, we want to help Australian and New Zealand companies capitalise on their new product ideas and IP, move through development efficiently, and launch their products in global markets, in a timely manner.

With Adjutor’s specialised knowledge and an expert network including in- country consultants all around the world, we are extremely well positioned to do this.

We look forward to more local engagement and some interesting projects in future.

Dr Rosalie Cull

More recent articles

  • Regulation of In Vivo CAR‑T Therapies

    Regulation of In Vivo CAR‑T Therapies

    Emerging Regulatory Frameworks for Programmable Immune Engineering Introduction In vivo CAR‑T therapy represents one of the most scientifically disruptive developments in modern biotechnology. Unlike traditional CAR‑T therapies, where T cells are removed from the patient, genetically engineered ex vivo, expanded, and reinfused, in vivo CAR‑T platforms aim to genetically program immune cells directly inside the…

  • From Sequential to Strategic

    From Sequential to Strategic

    How Smart Biotech Companies Are Winning in Accelerated Global Approval Pathways The global biotechnology regulatory environment is no longer just accelerating, it is fragmenting into a set of strategic choices that materially impact time to market, capital efficiency, and valuation. Companies that actively design multi-market regulatory strategies early are gaining measurable advantages. Those that don’t…

  • Orphan and Rare Diseases in 2026

    Orphan and Rare Diseases in 2026

    How Australia Accelerates Global Development A Maturing Global Rare Disease Landscape. In rare diseases, time equals patient impact. Leveraging Australia’s advantages enables faster, smarter global development. What are Orphan and Rare Diseases? Orphan and rare diseases are conditions that affect a small percentage of the population, often defined as impacting fewer than 1 in 2,000…